The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | The need to improve the characterization of CHIP in AL amyloidosis
Paolo Lopedote, MD, St Elizabeth’s Medical Center, Boston, MA, discusses the need to better characterize the clinical and molecular features associated with clonal hematopoiesis of indeterminate potential (CHIP) in patients with light chain (AL) amyloidosis. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
